Today: 9 June 2026
UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom
9 February 2026
1 min read

UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom

New York, February 9, 2026, 11:39 EST — Regular session

UnitedHealth Group Incorporated (UNH) inched up 0.3% to $277.44 by late morning Monday. Shares moved within a range of $273.88 to $278.36.

Even a tiny change like that matters, since UNH’s fortunes are still tightly linked to Medicare Advantage—those private senior and disability plans shaped by federal payment policies. The Centers for Medicare & Medicaid Services has floated its 2027 Advance Notice, flagging just a 0.09% bump in average payments. Comments are open through Feb. 25, and the agency is due to lock in the final rate by April 6.

Stocks in the U.S. got off to a mixed start this morning. Investors kept an eye on interest rate signals following last week’s tech slump. The Dow slipped roughly 0.3%. The S&P 500 was little changed, while the Nasdaq managed a slight uptick, according to Reuters.

UnitedHealth posted 2025 revenue of $447.6 billion on Jan. 27, a 12% increase, and projected 2026 revenue to top $439.0 billion with adjusted earnings expected to exceed $17.75 per share. CEO Stephen Hemsley, in prepared comments, said the company “confronted challenges directly” and wrapped up 2025 “as a much stronger company.” UnitedHealth Group

Investors didn’t like the news: shares dropped up to 19% on Jan. 27 after the company signaled its first revenue drop since 1989, according to Reuters. Hemsley talked up noticeable “momentum” inside the company, but UnitedHealthcare chief Tim Noel flagged “meaningful benefit reductions” coming. Morningstar’s Julie Utterback told investors looking for a fast turnaround they “may have to wait longer than hoped.” For 2026, UnitedHealth projected its medical care ratio—how much of premiums go toward medical costs—at roughly 88.8%, an important profit metric for the sector. Reuters

UnitedHealth isn’t alone when it comes to rising costs. Molina Healthcare on Feb. 6 slashed its 2026 profit outlook, blaming higher medical expenses, and announced it will walk away from Medicare Advantage prescription drug plans in 2027. CEO Joseph Zubretsky called 2026 a “trough year” for Medicaid margins. Reuters

UNH faces a tough setup right now: reimbursement remains squeezed, and care utilization just won’t cool off. Insurers could try to prop up margins by cutting back on benefits or pulling back from certain markets—though moves like that risk slowing down membership gains and drawing extra attention.

Scrutiny isn’t new. Back in January, a Senate committee report accused UnitedHealth of employing aggressive risk-adjustment coding tactics—essentially, a method that increases payments for plans serving sicker Medicare Advantage patients—to ramp up reimbursement. The company pushed back, saying it disagreed with the report’s take and insists its programs follow regulations.

No obvious company news to kick things off Monday, so traders will be eyeing the U.S. macro calendar. First up: the January Employment Situation lands at 8:30 a.m. ET on Feb. 11. Just two days later, January’s Consumer Price Index hits at 8:30 a.m. ET on Feb. 13, per Labor Department schedules.

Stock Market Today

  • Aker BP Share Price Surges Amid Valuation Debate
    June 9, 2026, 11:54 AM EDT. Aker BP (OB:AKRBP) shares climbed to NOK347.7, marking a 55.05% total shareholder return over one year, outperforming peers in Norway's energy sector. Despite this momentum, the stock trades at an 8.6% premium over a fair value of NOK320.11, raising questions about valuation. The company aims to sustain production above 500,000 barrels per day past 2030, backed by projects like Yggdrasil and Johan Sverdrup, supporting revenue growth. Yet, potential risks include higher emissions costs and delays in key developments. Analysts offer cautious pricing, but a discounted cash flow (DCF) model from Simply Wall St suggests a much higher intrinsic value of NOK1,769.75, indicating significant undervaluation. Investors face a valuation divide between conservative targets and optimistic cash flow projections.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
Uber’s new ride-booking kiosks and Adyen expansion spotlight fintech’s 2026 embedded-finance push
Previous Story

Uber’s new ride-booking kiosks and Adyen expansion spotlight fintech’s 2026 embedded-finance push

Silver price jumps again as dollar slips — here’s what traders watch next
Next Story

Silver price jumps again as dollar slips — here’s what traders watch next

Go toTop